IPO Guru
Bajaj

Integris Medtech IPO Could Open 27 November: ₹2,500–3,000 Crore Issue, Says ET

Abhishek Vohera By Abhishek Vohera Published: 3 min read
Integris Medtech IPO Could Open 27 November: ₹2,500–3,000 Crore Issue, Says ET

The Integris Medtech IPO may open on 27 November and close on 1 December, as per an Economic Times report. The Gurugram-based medical devices company wants to raise ₹2,500–3,000 crore. The company has not confirmed the dates or the size.

What ET reports

ET cites people familiar with the matter. The company and its bankers did not reply to ET's emails before it published.

ItemAs reported
Opens27 November 2026
Closes1 December 2026
Issue size₹2,500–3,000 crore
StructureFresh issue plus offer for sale (OFS)
Lead managersICICI Securities, Axis Capital, Citigroup, IIFL Capital Services

The OFS is the part where existing shareholders sell their shares. The price band, lot size and listing date are not out yet. They will come with the red herring prospectus (RHP), the final offer document.

Where will the money go?

The company plans to use 85% of the net proceeds from the fresh issue to repay debt. The loans sit in its wholly owned and step-down subsidiaries. So most of the new money goes to clearing debt.

Integris makes cardiovascular devices, clinical diagnostics products and laboratory solutions. It sells them in markets outside India as well.

What does the company do?

Integris Medtech is a global medical products and laboratory solutions company. It has three main businesses. These are cardiovascular devices, clinical diagnostics and scientific laboratory solutions.

It develops, makes and sells a wide range of medical devices and laboratory products. Its customers are in international markets, not only in India. The company is headquartered in Gurugram.

Why the debt repayment matters

Most of the fresh money will not build new factories. It will pay down loans held by subsidiaries. Lower debt can cut the interest the company pays each year, but it does not add new business by itself.

The RHP should list which subsidiary loans will be repaid and how much each gets. Read that section when it is out. The promoters and other sellers in the OFS get the money from their own shares, not the company.

What our data shows

The size looks very different from our last report. In October, the company cut its fresh issue to ₹600 crore from ₹925 crore, as we covered in our earlier post on the Integris Medtech IPO. If ET's size is right, the OFS would be the bigger part, at more than ₹1,900 crore. That is our arithmetic, not a reported figure.

What happens next

Watch for the RHP, which should carry the price band and the exact OFS size. Until then, treat the dates and size as a report. You can track every dated issue on our upcoming mainboard IPO page. The report is on The Economic Times.

Tags: #Upcoming IPO #IPO News #Mainboard IPO #Integris Medtech
Abhishek Vohera
Written by

Abhishek Vohera

Founder, IPO Guru

Abhishek Vohera is the founder of IPO Guru. He decodes Indian IPOs and stock market trends for retail investors, cutting through the noise with clear, actionable insights backed by years of market experience.

Don't Miss the Next Big IPO

Join thousands of investors tracking real-time GMP and allotment updates.

Advertisement